Home › Funds › Slocum, Gordon & Co LLP › ABT

Slocum, Gordon & Co LLP position in ABT

ABBOTT LABORATORIES · Health Care

Slocum, Gordon & Co LLP reported holding 3,807 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$376K, representing 0.26% of its reported portfolio and ranking #48 among its reported holdings. Slocum, Gordon & Co LLP has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)3.81K sh
Reported value held$376.25K
Portfolio Weight0.26%
First reportedQ4 2023
Last changeHold
Updated2026-10-21

Last updated: 2026-10-21 · Source: SEC EDGAR Form 13F-HR

How Slocum, Gordon & Co LLP's ABT position evolved

Slocum, Gordon & Co LLP first disclosed a stake in ABT in Q4 2023 at 4,700 shares (US$517K). The position peaked in Q2 2025 at 4,250 shares, worth US$578K. Across 12 filings, Slocum, Gordon & Co LLP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 3,807 shares valued at US$376K.

Quarter by quarter

QuarterSharesValueChange
Q4 2023 4.70K $517.33K New
Q1 2024 4.25K $483.05K Reduce
Q2 2024 4.25K $441.62K Hold
Q3 2024 4.25K $484.54K Hold
Q4 2024 4.25K $480.71K Hold
Q1 2025 4.25K $563.76K Hold
Q2 2025 4.25K $578.04K Hold
Q3 2025 4.25K $569.25K Hold
Q4 2025 4.25K $532.48K Hold
Q1 2026 3.80K $390.15K Reduce
Q2 2026 3.81K $345.45K Hold
Q3 2026 3.81K $376.25K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Slocum, Gordon & Co LLP held ABT?

Slocum, Gordon & Co LLP has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is Slocum, Gordon & Co LLP's current position in ABT?

As of Q3 2026, Slocum, Gordon & Co LLP holds 3.81K shares of ABT (ABBOTT LABORATORIES), valued at $376.25K, representing 0.26% of its reported portfolio and ranking #48.

Has Slocum, Gordon & Co LLP been buying or selling ABT?

In the latest 13F filing (Q3 2026), Slocum, Gordon & Co LLP held unchanged its position in ABT. The position peaked in Q2 2025 at 4.25K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.